Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2023 / Articles / Aug / Exploring Alzheimer’s in Women
Discovery & Development Drug Discovery Formulation Research News Formulation

Exploring Alzheimer’s in Women

Studying the link between Alzheimer’s risk, estrogen levels, and menopausal status in women

By Jamie Irvine 08/31/2023 2 min read

Share

The disparity between the number of men and women diagnosed with Alzheimer’s disease is striking. Statistics in the US suggest that two thirds of those with the disease are women (1) – results that are consistent with previous studies conducted in Sweden, Taiwan, and Europe. But despite the alarming nature of these findings, Alzheimer’s research focused on women is uncommon.

To fill this gap, researchers from Rice University have won a three-year grant from the National Institutes of Health (NIH) to look at how Alzheimer’s risk, estrogen levels, and menopausal status interact with memory-related brain function and behavioral outcomes in women aged 35–80.

According to the researchers, although the prevalence of Alzheimer’s disease and the severity of symptoms is greater in females relative to males, the impact of estrogen declines with menopause is underexplored. Estrogen has a large influence on cognition, with strong ties to memory function. Therefore, the loss of this neuroprotective sex hormone with menopause may contribute to increased risk for Alzheimer’s disease in aging females.

“Historically, females have been viewed as more ‘variable’ when it comes to hormone fluctuations across the menstrual cycle. This was thought to make females less-reliable research subjects. However, given recent movements for the advancement of women’s health research, the potential link between menopause and Alzheimer’s disease is beginning to receive the attention it deserves,” says Hannah Ballard, lead researcher and Rice University postdoctoral fellow.

Research has also suggested that estrogen is important for protecting against the build-up of amyloid plaques – a neurological hallmark of Alzheimer’s disease. And considering that estrogen loss occurs around the same timeframe that Alzheimer’s disease pathology appears, perimenopause may represent a critical period for the efficacy of therapeutic strategies or treatment interventions.

The teams’ ongoing study involves a memory task sensitive to age-related declines, in addition to structural, functional, and resting-state MRI to evaluate brain function and cognition over the course of the menopausal transition. Ballard says, “To assess estrogen levels and risk for Alzheimer’s disease, we will collect a small saliva sample for hormone and genetic testing. This study will be performed in healthy adult females, spanning various stages from reproductive to postmenopausal years.”

This study is still actively recruiting participants. If interested, please contact the Neuroscience of Memory, Mood, & Aging Lab at memory@rice.edu or call (713) 348-8164 for more information.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. W Thies, L Bleiler, “2013 Alzheimer’s disease facts and figures,” 9, 2 (2013). PMID: 23507120.

About the Author(s)

Jamie Irvine

Associate Editor, The Medicine Maker

More Articles by Jamie Irvine

False

Advertisement

Recommended

False

Related Content

Understanding the H5N1 Threat
Vaccines Drug Discovery
Understanding the H5N1 Threat

February 3, 2025

4 min read

With new cases of avian influenza appearing, what does this mean for global health and what are drug developers doing about it?

Battle of the Superbugs
Drug Discovery Technology and Equipment
Battle of the Superbugs

December 1, 2014

0 min read

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Antibiotics: Going With the Flow
Drug Discovery Small Molecules
Antibiotics: Going With the Flow

April 2, 2025

2 min read

How fluid flow through the body can affect the ways in which antibiotics work.

Combatting the Side Effects of Treatments for Parkinson’s
Drug Discovery Small Molecules
Combatting the Side Effects of Treatments for Parkinson’s

April 7, 2025

4 min read

Celon Pharma CEO hopes their new compound could be a potential breakthrough for Parkinson’s patients.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.